Efficacy of intermittently administered dasatinib with a reduced dose in an elderly patient with chronic myeloid leukemia
Author:
Affiliation:
1. Department of Hematology; Sapporo Hokuyu Hospital; Sapporo Japan
Publisher
Wiley
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/ggi.12604/fullpdf
Reference9 articles.
1. “Real-life” results of frontline treatment with imatinib in older patients (>65 years) with newly diagnosed chronic myelogenous leukemia;Latagliata;Leuk Res,2010
2. Evaluation of tolerability and efficacy on imatinib mesylate in elderly patients with chronic phase CML: ELDERGLI study;Sanchez-Gujio;Leuk Res,2011
3. European LeukemiaNet recommendations for the treatment of chronic myeloid leukemia;Baccarani;Blood,2013
4. Chronic myelogenous leukemia, version 1.2014;O'Brien;J Natl Compr Canc Netw,2013
5. Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patients data from five clinical trials;Jain;Lancet Haematol,2015
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Long-term follow-up of efficacy and safety in elderly patients with chronic myeloid leukemia treated with intermittent low dose dasatinib therapy;Leukemia Research Reports;2024
2. Analysis of drug transporter gene polymorphisms in an elderly patient with chronic myeloid leukemia successfully treated with intermittent low‐dose dasatinib;Geriatrics & Gerontology International;2023-11-03
3. Severe adverse events by tyrosine kinase inhibitors decrease survival rates in patients with newly diagnosed chronic-phase chronic myeloid leukemia;European Journal of Haematology;2018-05-23
4. Plasma and intracellular concentrations in an elderly patient with chronic myeloid leukemia receiving low-dose dasatinib therapy;Geriatrics & Gerontology International;2018-03
5. Dasatinib dose management for the treatment of chronic myeloid leukemia;Cancer;2018-01-25
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3